| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 08/21/2001 | CA2093793C Alkylidene analogs of 1'-aminospiro¬isoquinoline-4(1h),-3'-pyrrolidine|1,2',3,5'(2h)-tetrones useful as aldose reductase inhibitors |
| 08/21/2001 | CA2060652C N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives |
| 08/16/2001 | WO2001059128A2 Novel elongase gene and method for producing multiple-unsaturated fatty acids |
| 08/16/2001 | WO2001059127A2 Drug metabolizing enzymes |
| 08/16/2001 | WO2001059107A1 Novel scavenger receptors |
| 08/16/2001 | WO2001059106A1 Novel g protein-coupled receptor proteins and dnas thereof |
| 08/16/2001 | WO2001059071A2 Methods of preparing and using a viral vector library |
| 08/16/2001 | WO2001058956A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | WO2001058945A1 Dna encoding human vanilloid receptor vr3 |
| 08/16/2001 | WO2001058937A2 Interferon-alpha induced genes |
| 08/16/2001 | WO2001058906A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058902A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058900A1 1h-imidazopyridine derivatives |
| 08/16/2001 | WO2001058899A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| 08/16/2001 | WO2001058897A1 Benzthiazoles as tnf and pde-iv inhibitors |
| 08/16/2001 | WO2001058896A1 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 08/16/2001 | WO2001058895A1 Benzofuran carboxamides and their therapeutic use |
| 08/16/2001 | WO2001058886A1 Dipeptide nitrile cathepsin k inhibitors |
| 08/16/2001 | WO2001058875A2 Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives |
| 08/16/2001 | WO2001058454A1 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
| 08/16/2001 | WO2001058283A1 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| 08/16/2001 | WO2001010413A3 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 08/16/2001 | WO2001010381A3 Methods for treating or preventing pain and anxiety |
| 08/16/2001 | WO2001009115A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
| 08/16/2001 | WO2001007435A3 N-(indolcarbonyl-)piperazin derivatives als 5-ht2a-receptor ligands |
| 08/16/2001 | WO2001006989A3 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 08/16/2001 | WO2001002569A3 Human immune response molecules |
| 08/16/2001 | WO2000056356B1 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 08/16/2001 | WO2000023603A9 Methods of treatment of type 2 diabetes |
| 08/16/2001 | WO1999050658A3 Methods and compounds for modulating nuclear receptor activity |
| 08/16/2001 | US20010014740 Method of producing heterocyclic derivatives |
| 08/16/2001 | US20010014696 Therapeutic compositions (II) |
| 08/16/2001 | US20010014689 Nervous system disorders |
| 08/16/2001 | US20010014669 Method for preventing or treating elevated blood lipid level-related diseases by administering rutin and quercetin |
| 08/16/2001 | US20010014454 Novel metal complexes |
| 08/16/2001 | US20010014357 Citrus peel extract as inhibitor of ACYL coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 08/16/2001 | US20010014323 For use in investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency |
| 08/16/2001 | EP1144997A3 Methods and compounds for modulating nuclear receptor activity |
| 08/16/2001 | EP1123928A1 1,5-benzodiazepine compounds, process for producing the same, and medicine |
| 08/16/2001 | EP1123925A1 Process for preparation of substituted pyridines |
| 08/16/2001 | EP1123924A1 Substituted pyridines as HMG-COA reductase inhibitors |
| 08/16/2001 | EP1123921A1 Vitamin d 3? derivatives and remedies for inflammatory respiratory diseases containing the same |
| 08/16/2001 | EP1123717A2 Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
| 08/16/2001 | EP1123414A1 Antisense modulation of integrin alpha 4 expression |
| 08/16/2001 | EP1123314A2 USE OF A CYTOKINE-PRODUCING $i(LACTOCOCCUS) STRAIN TO TREAT COLITIS |
| 08/16/2001 | EP1123309A2 Cyclic tetrapeptides and their use as histone deacetylase inhibitor |
| 08/16/2001 | EP1123297A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123295A1 Bicyclic nitrogen heterocycles |
| 08/16/2001 | EP1123292A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123279A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123269A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123268A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123267A1 New compounds, their preparation and use |
| 08/16/2001 | EP1123103A1 A process for producing an iron-dextran compound |
| 08/16/2001 | EP1123097A1 Pharmaceutical composition containing decursin |
| 08/16/2001 | EP1123096A1 Bioflavonoids as plasma high density lipoprotein level increasing agent |
| 08/16/2001 | EP1123094A1 Therapeutic compositions (ii) |
| 08/16/2001 | EP1123093A1 Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiquinones and methods of using same |
| 08/16/2001 | EP1123086A2 Artificial antigen-specific cells and related methods |
| 08/16/2001 | EP1123008A2 Preparation and use of solidified oils |
| 08/16/2001 | EP1035851B1 Endothelin receptor antagonists for combating hyperlipidaemia |
| 08/16/2001 | EP0552256B1 Method of treating or preventing type 1 diabetes by oral administration of insulin |
| 08/16/2001 | CA2800450A1 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | CA2416343A1 Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 08/16/2001 | CA2400299A1 Dna encoding human vanilloid receptor vr3 |
| 08/16/2001 | CA2399873A1 Drug metabolizing enzymes |
| 08/16/2001 | CA2399421A1 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
| 08/16/2001 | CA2399349A1 Novel elongase gene and method for producing multiple-unsaturated fatty acids |
| 08/16/2001 | CA2399148A1 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | CA2399136A1 1h-imidazopyridine derivatives |
| 08/16/2001 | CA2398984A1 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| 08/16/2001 | CA2397254A1 Interferon-alpha induced genes |
| 08/15/2001 | CN1308677A Human tumour-derived polyptde hormone phosphatonin |
| 08/15/2001 | CN1308632A 'Beta'-carboline compound |
| 08/15/2001 | CN1308627A 11-Aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-aryl-benzo[b]anphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia |
| 08/15/2001 | CN1308626A Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia |
| 08/15/2001 | CN1308625A Naphtho [2,3-b] heteroar-4-yl derivatives |
| 08/15/2001 | CN1308624A Novel polyoxypropylenepolyoxyethylene vitamin E and preparation thereof |
| 08/15/2001 | CN1308622A Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| 08/15/2001 | CN1308621A Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| 08/15/2001 | CN1308620A Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
| 08/15/2001 | CN1308619A (2-acylaminothiazole-4-yl) acetic acid derivatives |
| 08/15/2001 | CN1308618A Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
| 08/15/2001 | CN1308609A Method of locking 1 & alpha, -OH of vitamin d compounds in axial orientation |
| 08/15/2001 | CN1308606A Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use pharmaceutical preparations comprising them |
| 08/15/2001 | CN1308604A 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia |
| 08/15/2001 | CN1308544A Treatment for diabetes |
| 08/15/2001 | CN1308539A Process for producing an iron-dextran compound |
| 08/15/2001 | CN1308536A Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 08/15/2001 | CN1308525A Transdermal plaster containing at least one active ingredient which infuences blood serum lipid levels |
| 08/15/2001 | CN1308523A Pellets having a core coated with a lipid lowering agent and a polymer |
| 08/15/2001 | CN1308520A Controlled release oral tablet having a unitary core |
| 08/15/2001 | CN1308492A Hypericin and i(hypericum) extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
| 08/15/2001 | CN1308069A Substittued (dihydro)benzoxazole and (dihydro)benzoxazine compound and their preparation and medicine composite |
| 08/15/2001 | CN1307886A Brain nourishing and intelligence promoting medicine and its preparation |
| 08/15/2001 | CN1307874A Diabetes treating medicine and its preparation |
| 08/15/2001 | CN1307812A Hypoglycemic soybean fiber powder |
| 08/15/2001 | CN1069538C Typhlosis-resistant liquid for ophthalmopathy as complication of diabetes |
| 08/15/2001 | CN1069537C Medicine for weight-reducing and beautifying |
| 08/15/2001 | CN1069536C Novel medicine for treating diabetes and preparation process thereof |